Theralase Advances Anti-Cancer Technology Platform
Moving toward an Investigational New Drug (IND) application from the FDA and Health Canada
Theralase Technologies Inc. announced today that it has advanced its anti-cancer technology platform through an executed research agreement with Acadia University. Under the terms of the agreement, Acadia will supply initial quantities of Theralase's lead Photo Dynamic Compounds (PDCs) and the Standard Operating Procedures (SOPs) of how to synthesize them.
The lead PDCs will be used by Theralase to commence toxicity analysis and manufacturing ramp up via Contract Manufacturing Organization (CMO); both mandatory prerequisites in the evolution towards an approved Investigational New Drug (IND) application from the FDA and Health Canada. With larger quantities of the PDCs in hand and an approved IND; Theralase would be in the position to commence a Phase 1/2a human clinical trial for the lead indication of bladder cancer, as early as 1Q2015.
To find out more about how the McFarland Labs are involved, Click Here to read the full story.